Stock Information
symbol line chart

KMDAKamada Ltd

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Amir London

Location

N/A, Israel

Exchange

Nasdaq

Website

https://kamada.com

Summary

Kamada Ltd.

Company Info

CEO

Amir London

Location

N/A, Israel

Exchange

Nasdaq

Website

https://kamada.com

Summary

Kamada Ltd.

AI Insights for KMDA
2 min read

Quick Summary

Kamada Ltd. is a biopharmaceutical company based in Rehovot, Israel, specializing in the development, production, and marketing of plasma-derived protein therapeutics designed to address rare and orphan diseases. The company operates globally, with its proprietary and distribution segments offering a variety of treatments for chronic conditions, including therapies for Alpha-1 Antitrypsin Deficiency (AATD) and multiple respiratory and pulmonary disorders. Kamada's main customers include hospitals, clinics, government agencies, and specialty pharmacies, particularly those treating rare pulmonary conditions. The company has established a significant presence in over 30 countries, leveraging relationships with healthcare providers, regulatory agencies, and distribution partners. Kamada’s expertise in plasma collection and fractionation enables it to supply both proprietary and contract-manufactured products to meet unmet medical needs in specialized patient populations.

The Bull Case

  • Kamada's primary strengths lie in its expertise in plasma-derived therapeutics for orphan and rare diseases, which positions it as a leader in a specialized and less crowded market segment.
  • The company has a diversified portfolio with both proprietary and distribution products, strong international presence, and established long-term customer contracts.
  • Operationally, Kamada demonstrates solid financial management, evidenced by strong EBITDA growth and a healthy cash balance.
  • Its investment in expanding plasma collection infrastructure supports future scalability and revenue diversification.
  • The company’s focus on innovation and regulatory compliance also ensures sustained competitiveness and product quality.

The Bear Case

  • Despite recent successes, Kamada faces challenges related to declining royalties from key products like Glassia, and occasional underperformance of products such as CYTOGAM.
  • The discontinuation of the inhaled AAT trial highlights the risk inherent in clinical development.
  • The company also faces rising operating expenses that could pressure margins.
  • Additionally, Kamada operates in highly regulated markets, which adds complexity and potential delays.
  • Increased competition from larger, well-funded plasma therapeutics companies could threaten market share over time.

Key Risks

  • Risks to Kamada include clinical trial failures, as evidenced by the discontinued inhaled AAT program, which can lead to sunk R&D costs and missed commercial opportunities.
  • The company faces intense competition from established global plasma therapeutics firms, which could pressure prices and market share.
  • Regulatory hurdles and potential delays present ongoing threats, especially as Kamada seeks to expand internationally.
  • Changes in healthcare reimbursement, supply chain disruptions, or adverse changes in product mix affecting gross margins are additional concerns.

What to Watch

UpcomingDuring the most recent quarter, Kamada reported strong revenue growth of 11% and a 35% increase in adjusted EBITDA, demonstrating resilience in its core business.
UpcomingA new plasma collection center opened in Houston, expected to drive $8–10M in annual revenue.
UpcomingThe company also secured a significant extension of its Canadian Blood Services contract, ensuring stable sales for four key plasma products.
ExpectedLooking ahead to the next quarter, Kamada is expected to continue expanding its plasma collection capabilities, with a new center planned in San Antonio, Texas.

Price Drivers

  • Kamada's stock price is primarily driven by its strong earnings growth, especially double-digit profitable growth projections for 2024–2026.
  • Performance of its main products, especially Glassia, and the success of new plasma collection centers have a significant impact.
  • The company's ability to secure and extend key contracts, such as the Canadian Blood Services tender, also influences valuation.
  • Broader sector growth, clinical trial progress, and global expansion plans are additional drivers.

Recent News

  • Kamada recently made headlines for opening a new plasma collection center in Houston—one of the largest of its kind in the U.S.—and for planning another facility in San Antonio.
  • The company confirmed a two-year extension of its Canadian Blood Services tender, securing stable sales through at least 2028.
  • Despite discontinuing its key inhaled AAT Phase 3 trial, Kamada maintained its strong 2025 outlook, projecting further revenue and EBITDA growth.
  • Financial results highlighted robust performance, with marked increases in revenue, EBITDA, and net income.

Market Trends

  • The blood plasma derivatives sector is experiencing strong global growth, with the market expected to expand from $32 billion in 2026 to nearly $48 billion by 2032 at a 6.7% CAGR.
  • Advances in biotechnology, rising prevalence of rare and chronic diseases, and increased healthcare spending are fueling demand.
  • Regulatory guidance and improvements in supply chains are shaping a dynamic competitive landscape.
  • New biosimilar launches, strategic partnerships, and broader clinical access are key trends.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on KMDA

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show